Researchers from the National University of Singapore (NUS), in collaboration with Peking University, China, have made a discovery regarding the TRPV1 (transient receptor potential vanilloid 1) ion ...
With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...